Company Profile

Snowdon Pharmaceuticals Inc (AKA: Snowdon, Inc)
Profile last edited on: 6/4/19      CAGE: 4GSA4      UEI:

Business Identifier: Small-molecule therapeutics
Year Founded
2005
First Award
2008
Latest Award
2010
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1 Deer Park Drive Suite H-3
Monmouth Junction, NJ 08852
   (609) 577-4413
   info@snowdonpharma.com
   www.snowdonpharma.com
Location: Single
Congr. District: 12
County: Middlesx

Public Profile

Snowdon Inc. is a pharmaceutical company focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. The company’s projects include a preclinical compound SND-121 for the treatment for neuropathic pain; SND-159 for tuberculosis; and SND-226 for toxoplasmosis. The firm was also pursuing early stage discovery projects aimed at novel medical treatments for neurological disorders, such as Fragile X Syndrome, which is the most common known cause of autism and autistic-like behaviors. Snowdon Pharmaceuticals Inc. had been providing computational tools rapidly to identify high-value molecules from their library of vendor-available compounds. Website still functional but no added content post c. 200

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $628,578
Project Title: Development Of An Inhibitor Of Toxoplasma Gondii
2008 1 NIH $122,971
Project Title: Computer-Aided Design, Synthesis, And Testing Of A Novel Family Of Triazole-Based
2008 1 NIH $130,000
Project Title: Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases

Key People / Management

  Stephen D Albano -- interim CEO

  Michael Becker -- Senior Partner

  James M Golubieski -- Board of Directors, President of FVCG

  Susan M Welsh -- past President

  William J (Bill) Welsh -- founder

  Richard D Wood -- Vice President of Research and Development